Skip to main content
Premium Trial:

Request an Annual Quote

Morphosys, GeneFrontier Expand HuCAL Deal to Include Antibody Development

NEW YORK (GenomeWeb News) — Morphosys today said it has expanded a 2-year-old marketing agreement with GeneFrontier to include HuCAL-based research, and the sales of any resulting antibody products.
 
The original agreement, signed in 2004, gave Tokyo-based GeneFrontier rights to market the Human Combinatorial Antibody Library technology in Japan for research and therapeutic applications.
 
Under the expanded deal, GeneFrontier will use the HuCAL Gold library to develop antibodies, and it has installed the technology in its Tokyo lab to conduct the research.
 
GeneFrontier paid Morphosys “a financial compensation” for access to the technology, Morphosys said. The companies also will share commercialization rights to antibodies discovered by GeneFrontier and its research partners.
 
Financial terms of the agreement were not released.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.